Calliditas Therapeutics AB (publ) (CALT)
| Previous close | 19.90 |
| Open | 20.05 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 20.05 - 20.20 |
| 52-week range | 15.25 - 29.30 |
| Volume | |
| Avg. volume | 6,525 |
| Market cap | 542.031M |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN). The analysis showed statistically significant improvements in progression-free survival (PFS), as well as in overall survival (OS), with statistically significant changes in tumor biology consisten
- PR Newswire
Calliditas Therapeutics' 2023 Annual Report Published
Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available at the company's website: www.calliditas.com
- PR Newswire
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine ration (UPCR) and estimated glomerular filtration rate (eGFR) at 9 months across all IgAN patients, including those who had previously received Nefecon in the NefIgArd study.
